tACS-MI: A Pilot Study of Non-invasive Brain Stimulation to Boost the Efficacy of Psychotherapy in a Community Sample of People Who Drink Alcohol

Sponsor
The Mind Research Network (Other)
Overall Status
Recruiting
CT.gov ID
NCT04770025
Collaborator
National Institute of General Medical Sciences (NIGMS) (NIH)
75
1
3
29.9
2.5

Study Details

Study Description

Brief Summary

The goal of this small (n=75) proof-of-concept randomized clinical trial is to test the effects of transcranial alternating current stimulation (tACS) during motivational interviewing (MI) sessions with participants who drink at above the low-risk level. Participants will be randomized to receive either MI with active stimulation, MI with sham stimulation, or a delayed treatment group that receives MI with no stimulation. Measures will include brain imaging, alcohol use, cannabis use, risk-taking behavior, emotions, and others. Participants who are randomized to the delayed-treatment group will not receive brain imaging.

Condition or Disease Intervention/Treatment Phase
  • Device: High-density transcranial alternating current stimulation
  • Device: Sham stimulation
  • Behavioral: Motivational interviewing
Phase 2

Detailed Description

This proof-of-concept randomized clinical trial will recruit n=75 people with problematic levels of drinking who are considering treatment for their alcohol use. These participants will be randomized to one of three conditions: a condition that applies active tACS during an MI session (MI+tACS), a condition that applies sham stimulation during an MI session (MI+sham), or a waitlist control condition (MI-only). Only participants the MI+tACS and MI+sham conditions will be included in the brain imaging portion of the study. One month after their intervention session, all participants will report their use of alcohol in the prior 30 days via an online assessment battery. This will allow us to test the effects of tACS on within-session client speech and outcomes.

Participants will have magnetoencephalography (MEG) scans including rest and an alcohol cue task to measure the acute effects of brain stimulation. Participants will also have MRI scans including structure and rest. The Motivational Interviewing Skill Code (MISC 2.5) and the CASAA Application for Coding Treatment Interactions (CACTI) will be used to assess counselor and participant speech in the recorded MI sessions and to ensure that sessions comply with the principles of MI.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Double-blind proof-of-concept randomized clinical trialDouble-blind proof-of-concept randomized clinical trial
Masking:
Double (Participant, Care Provider)
Masking Description:
Double (Participant, Providers/Research Assistants)
Primary Purpose:
Other
Official Title:
Transcranial Alternating Current Stimulation to Boost the Efficacy of Motivational Interviewing
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Aug 31, 2022
Anticipated Study Completion Date :
Feb 28, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: MI with tACS

Motivational interviewing with concurrent active stimulation

Device: High-density transcranial alternating current stimulation
High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range

Behavioral: Motivational interviewing
Motivational interviewing session focused on alcohol use, approximately 30 minutes in length

Sham Comparator: MI with sham

Motivational interviewing with concurrent sham stimulation

Device: Sham stimulation
High-density electrode configuration with sham stimulation

Behavioral: Motivational interviewing
Motivational interviewing session focused on alcohol use, approximately 30 minutes in length

Active Comparator: MI-only

Motivational interviewing only, delayed treatment control

Behavioral: Motivational interviewing
Motivational interviewing session focused on alcohol use, approximately 30 minutes in length

Outcome Measures

Primary Outcome Measures

  1. Heavy drinking days [One month]

    Number of heavy drinking days in the prior 30 days

Secondary Outcome Measures

  1. Drinks per drinking day [One month]

    Number of drinks per drink day in the prior 30 days

  2. Percent days abstinent [One month]

    Percent days abstinent in the prior 30 days

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  • Self-identify as having problem drinking

  • Right-handed

  • Age 21-60 years

  • AUDIT score indicating risky drinking

Exclusion criteria:
  • Left-handed or ambidextrous

  • Currently engaged in treatment for alcohol use disorder

  • Receiving treatment for alcohol use disorder within the prior 12 months

  • History of brain injury or neurological diagnosis

  • Evidence of current psychosis

  • Past-year substance use disorder other than alcohol, marijuana, or nicotine

  • Current or history of severe alcohol withdrawal

  • MRI/tACS contraindications including pregnancy

  • Impaired hearing (psychotherapy using American Sign Language is not possible within the scope of the proposed study)

  • Insufficient corrected visual acuity to complete the assessment instruments

  • Unable to read/speak English fluently

  • Unable to provide valid informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Mind Research Network Albuquerque New Mexico United States 87106

Sponsors and Collaborators

  • The Mind Research Network
  • National Institute of General Medical Sciences (NIGMS)

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
The Mind Research Network
ClinicalTrials.gov Identifier:
NCT04770025
Other Study ID Numbers:
  • 20-010
  • P30GM122734
First Posted:
Feb 25, 2021
Last Update Posted:
Apr 6, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by The Mind Research Network
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2022